DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
keyhole limpet hemocyanin is an investigational drug.
There have been 29 clinical trials for keyhole limpet hemocyanin. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2011.
The most common disease conditions in clinical trials are Glioblastoma, Lymphoma, and Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), and John Sampson.
There are three hundred and seventy US patents protecting this investigational drug and three international patents.
Recent Clinical Trials for keyhole limpet hemocyanin
|A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma||Mount Sinai Hospital, New York||Phase 2|
|A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma||New York University School of Medicine||Phase 2|
|Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant||PCI Biotech AS||Phase 1|
Top disease conditions for keyhole limpet hemocyanin
Top clinical trial sponsors for keyhole limpet hemocyanin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|keyhole limpet hemocyanin||Start Trial||Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies||Kobenhavns Universitet (Copenhagen, DK) Cancer Research Technology Limited (London, GB)||Start Trial|
|keyhole limpet hemocyanin||Start Trial||Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same||Start Trial|
|keyhole limpet hemocyanin||Start Trial||Modulators of gamma-C-cytokine activity||BIONIZ, LLC (Irvine, CA)||Start Trial|
|keyhole limpet hemocyanin||Start Trial||Siderophore-based immunization against gram-negative bacteria||Massachusetts Institute of Technology (Cambridge, MA) The Regents of the University of California (Oakland, CA)||Start Trial|
|keyhole limpet hemocyanin||Start Trial||Aquaporin 2 protects cattle from ticks and tick-borne parasites||The United States of America, as represented by the Secretary of Agriculture (Washington, DC) Washington State University (Pullman, WA)||Start Trial|
|keyhole limpet hemocyanin||Start Trial||6-acetylmorphine analogs, and methods for their synthesis and use||ALERE SAN DIEGO, INC. (San Diego, CA)||Start Trial|
|keyhole limpet hemocyanin||Start Trial||Phosphohistidine and phosphotyrosine analogues||UNIVERSITY OF SHEFFIELD (Sheffield, GB)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|keyhole limpet hemocyanin||Australia||2007304590||2026-10-04||Start Trial|
|keyhole limpet hemocyanin||Canada||2665356||2026-10-04||Start Trial|
|keyhole limpet hemocyanin||Canada||2977261||2026-10-04||Start Trial|
|keyhole limpet hemocyanin||European Patent Office||2083868||2026-10-04||Start Trial|
|keyhole limpet hemocyanin||Japan||2010505775||2026-10-04||Start Trial|
|keyhole limpet hemocyanin||World Intellectual Property Organization (WIPO)||2008040362||2026-10-04||Start Trial|
|keyhole limpet hemocyanin||Australia||2015209140||2034-01-24||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|